Sarepta Therapeutics Announces Initiation of EMBARK, Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
October 04, 2021 at 07:00 am EDT
Sarepta Therapeutics, Inc. announced the initiation, in partnership with Roche, in the U.S. and countries around the world, of study SRP-9001-301, also known as EMBARK, a pivotal study of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) for the treatment of Duchenne muscular dystrophy. SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.